VitsGen’s IND Application for 177Lu-FAP-VG11 Injection for Advanced Malignant Solid Tumors Accepted by China’s NMPA CDE
Advancing the Frontier | Investigator-Initiated Trial of 177Lu-FAP-VG11 Injection in Advanced Solid Tumors Officially Launched
Dr. Keene Wei, Founder of Vitsgen, Invited to Speak at the 3rd Global Nuclear Medicine Development Summit 2026, Sharing Cutting-Edge Insights on Radiopharmaceutical Conjugate Design
Dr. Keene Wei, Founder of VitsGen, to Present Frontier Insights on Intelligent Design of Radiopharmaceuticals at the 2nd TRP Targeted Radiopharmaceutical Summit
VitsGen’s IND for Novel PSMA-Targeting Radioligand Therapy (177Lu-PSMA-VG01) in mCRPC Accepted by China’s CDE
